2021
A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M, Hui P. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 145: 1367-1378. PMID: 34673912, DOI: 10.5858/arpa.2021-0098-ra.Peer-Reviewed Original ResearchBiomarkers, TumorCarcinomaDNA Copy Number VariationsDNA Polymerase IIEndometrial NeoplasmsFemaleGene DosageHumansImmunohistochemistryMicrosatellite InstabilityMolecular Diagnostic TechniquesMutationPoly-ADP-Ribose Binding ProteinsPredictive Value of TestsPrognosisTerminology as TopicTumor Suppressor Protein p53Immunohistochemical and molecular pathological typing in the differential diagnosis and prognosis risk assessment of endometrial carcinoma
Wang M, Hui P. Immunohistochemical and molecular pathological typing in the differential diagnosis and prognosis risk assessment of endometrial carcinoma. 中华病理学杂志 2021, 50: 1078-1082. PMID: 34496509, DOI: 10.3760/cma.j.cn112151-20210628-00463.Peer-Reviewed Original Research
2019
Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma
Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. Journal Of Neuro-Oncology 2019, 144: 107-115. PMID: 31190317, DOI: 10.1007/s11060-019-03208-w.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaDiffusion-weighted imaging patternsMagnetic resonance imagingCentral nervous system lymphomaNervous system lymphomaSystem lymphomaPeripheral enhancementDWI patternsPCNSL casesImaging featuresPrognostic markerHuman immunodeficiency virus (HIV) infectionKaplan-Meier survival analysisDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaMedian overall survivalImmunodeficiency virus infectionPredictors of survivalSolid organ transplantationImmunoglobulin heavy chain gene rearrangementPeripheral contrast enhancementLog-rank testMajor risk factorHeavy chain gene rearrangementTen-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequencyPathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2013
Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational Analysis
Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML. Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational Analysis. Thyroid 2013, 23: 1525-1531. PMID: 23682579, DOI: 10.1089/thy.2013.0154.Peer-Reviewed Original ResearchConceptsTall cell variantPapillary thyroid microcarcinomaPapillary microcarcinomaCell variantLymphovascular invasionNode metastasisThyroid microcarcinomaAdvanced stageCentral compartment lymph node metastasisLateral cervical node metastasesStage III/IVACentral compartment lymph nodesLateral cervical nodesMultifocal papillary carcinomaLymph node dissectionCervical node metastasisLymph node metastasisPapillary thyroid carcinomaNode dissectionTotal thyroidectomyCervical nodesLymph nodesClinicopathologic featuresMultifocal tumorsAggressive featuresScreening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDNA Mutational AnalysisErbB ReceptorsExonsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingPhenotypePolymerase Chain ReactionPrecision MedicinePredictive Value of TestsPressurePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTissue FixationYoung AdultConceptsNon-small cell lung carcinomaCore needle biopsyCell lung carcinomaKRAS mutationsNSCLC patientsSurgical resectionEGFR mutationsLung carcinomaNeedle biopsyKRAS mutation analysisTyrosine kinase inhibitorsKRAS gene mutationsDirect sequencingMutation analysisFemale patientsAdenocarcinoma componentLung cancerPatientsEGFRExon 19Kinase inhibitorsExon 18Gene mutationsStatistical significanceResectionIdentification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBiomarkers, TumorBone NeoplasmsCytodiagnosisDNA, NeoplasmErbB ReceptorsFeasibility StudiesFemaleGene RearrangementHumansIn Situ Hybridization, FluorescenceLiver NeoplasmsLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesSoft Tissue NeoplasmsYoung AdultConceptsALK gene rearrangementMetastatic lung adenocarcinomaEGFR mutationsKRAS mutationsMetastatic tumorsEpidermal growth factor receptorLung adenocarcinomaCytological specimensGene rearrangementsMolecular testsMolecular alterationsKirsten rat sarcoma viral oncogene homolog (KRAS) mutationsALK gene rearrangement analysisAnaplastic lymphoma kinase (ALK) gene rearrangementEGFR T790M mutationRat sarcoma viral oncogene homolog mutationsCases of lungT790M mutationImportant therapeutic implicationsFine needle aspiratesGene rearrangement analysisCell block materialGrowth factor receptorRecurrent lungRecurrent adenocarcinoma
2011
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance. Acta Cytologica 2011, 55: 570-575. PMID: 22156468, DOI: 10.1159/000333274.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryCell Transformation, NeoplasticDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafRiskTerminology as TopicThyroid Cancer, PapillaryThyroid GlandThyroid NeoplasmsThyroid NoduleConceptsPapillary thyroid carcinomaBRAF mutation analysisBRAF mutationsUndetermined significanceFollicular lesionsUndetermined significance/follicular lesionFine needle aspiration cytology specimensAUS/FLUS categoryMutation analysisBRAF-positive casesIndeterminate thyroid FNAsAspiration cytology specimensRisk of malignancySurgical pathology outcomeFine-needle aspiration specimensBRAF mutation testingNegative predictive valueSurgical pathology reportsThyroid follicular lesionsPredictability of malignancyThyroid fine-needle aspiration specimensSurgical interventionFinal diagnosisPathology outcomesPathology reportsUse of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions
Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions. Cancer Cytopathology 2011, 119: 228-234. PMID: 21732551, DOI: 10.1002/cncy.20172.Peer-Reviewed Original ResearchConceptsLow-grade squamous intraepithelial lesionsHR-HPV testingHPV testingCIN 2Colposcopy rateHR-HPVRelative light units/cutoffCervical intraepithelial neoplasia 2High-risk human papillomavirusHR-HPV statusRLU/COIntraepithelial neoplasia 2Hybrid Capture 2Squamous intraepithelial lesionsCIN 1 lesionsLarge teaching hospitalNegative predictive valueLSIL cytologyHPV statusIntraepithelial lesionsCapture 2Human papillomavirusTeaching hospitalCytologic diagnosisSevere lesions
2010
Expression of glypican 3 in placental site trophoblastic tumor
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology 2010, 5: 64. PMID: 20868507, PMCID: PMC2954974, DOI: 10.1186/1746-1596-5-64.Peer-Reviewed Original ResearchConceptsPlacental site trophoblastic tumorPlacental site noduleInvasive cervical squamous cell carcinomaCervical squamous cell carcinomaNon-trophoblastic tumorsSquamous cell carcinomaTrophoblastic tumorCell carcinomaCytoplasmic stainingRare gestational trophoblastic neoplasmDiagnostic markerGestational trophoblastic neoplasmsGestational trophoblastic diseaseUseful diagnostic markerNon-neoplastic tissuesMembrane-bound heparan sulfate proteoglycanEndometrial adenocarcinomaUterine tumorsIntermediate trophoblastTrophoblastic diseaseTrophoblastic neoplasmsImmunohistochemical expressionHepatocellular carcinomaImmunohistochemical markersResultsEighty percent
2005
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-6379. PMID: 16174717, DOI: 10.1210/jc.2005-0987.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerBRAF mutation statusBRAF mutationsClinicopathological predictorsRisk stratificationClinicopathological outcomesThyroid cancerPTC subtypesMutation statusTumor stage III/IVStage I/II diseaseMultivariate analysisTumor BRAF mutation statusStage III/IVInitial tumor characteristicsLymph node metastasisPoor clinicopathological outcomesInitial surgeryRecurrent diseaseClinical courseIndependent predictorsNode metastasisClinicopathological characteristicsSubsequent recurrenceTreatment failure